- Home
- QSI vs AARD Comparison
QSI vs AARD Comparison
Compare QSI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- AARD
- Stock Information
- Founded
- QSI 2013
- AARD 2017
- Country
- QSI United States
- AARD United States
- Employees
- QSI N/A
- AARD N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- AARD Health Care
- Exchange
- QSI Nasdaq
- AARD Nasdaq
- Market Cap
- QSI 208.6M
- AARD 192.2M
- IPO Year
- QSI N/A
- AARD 2025
- Fundamental
- Price
- QSI $1.09
- AARD $7.97
- Analyst Decision
- QSI Strong Buy
- AARD Strong Buy
- Analyst Count
- QSI 3
- AARD 5
- Target Price
- QSI $2.38
- AARD $32.60
- AVG Volume (30 Days)
- QSI 6.1M
- AARD 94.0K
- Earning Date
- QSI 08-05-2025
- AARD 08-13-2025
- Dividend Yield
- QSI N/A
- AARD N/A
- EPS Growth
- QSI N/A
- AARD N/A
- EPS
- QSI N/A
- AARD N/A
- Revenue
- QSI $3,412,000.00
- AARD N/A
- Revenue This Year
- QSI $45.62
- AARD N/A
- Revenue Next Year
- QSI $218.03
- AARD N/A
- P/E Ratio
- QSI N/A
- AARD N/A
- Revenue Growth
- QSI 100.47
- AARD N/A
- 52 Week Low
- QSI $0.61
- AARD $4.88
- 52 Week High
- QSI $5.77
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- QSI 36.82
- AARD N/A
- Support Level
- QSI $0.95
- AARD N/A
- Resistance Level
- QSI $1.14
- AARD N/A
- Average True Range (ATR)
- QSI 0.07
- AARD 0.00
- MACD
- QSI 0.02
- AARD 0.00
- Stochastic Oscillator
- QSI 53.70
- AARD 0.00
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.